These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 23432647)
1. Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail. Fontebasso AM; Liu XY; Sturm D; Jabado N Brain Pathol; 2013 Mar; 23(2):210-6. PubMed ID: 23432647 [TBL] [Abstract][Full Text] [Related]
2. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Schwartzentruber J; Korshunov A; Liu XY; Jones DT; Pfaff E; Jacob K; Sturm D; Fontebasso AM; Quang DA; Tönjes M; Hovestadt V; Albrecht S; Kool M; Nantel A; Konermann C; Lindroth A; Jäger N; Rausch T; Ryzhova M; Korbel JO; Hielscher T; Hauser P; Garami M; Klekner A; Bognar L; Ebinger M; Schuhmann MU; Scheurlen W; Pekrun A; Frühwald MC; Roggendorf W; Kramm C; Dürken M; Atkinson J; Lepage P; Montpetit A; Zakrzewska M; Zakrzewski K; Liberski PP; Dong Z; Siegel P; Kulozik AE; Zapatka M; Guha A; Malkin D; Felsberg J; Reifenberger G; von Deimling A; Ichimura K; Collins VP; Witt H; Milde T; Witt O; Zhang C; Castelo-Branco P; Lichter P; Faury D; Tabori U; Plass C; Majewski J; Pfister SM; Jabado N Nature; 2012 Jan; 482(7384):226-31. PubMed ID: 22286061 [TBL] [Abstract][Full Text] [Related]
6. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3. Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271 [TBL] [Abstract][Full Text] [Related]
7. [Mutations in histone H3.3 and chromatin remodeling genes drive pediatric and young adult glioblastomas]. Khuong-Quang DA; Gerges N; Jabado N Med Sci (Paris); 2012 Oct; 28(10):809-12. PubMed ID: 23067407 [No Abstract] [Full Text] [Related]
8. Cerebral hemispheric glioblastoma with PNET-like morphology and histone H3.3 G34 mutation in younger patients: Report of three rare cases and diagnostic pitfalls. Cheng Y; Bao W; Wu Q Indian J Pathol Microbiol; 2020; 63(2):262-266. PubMed ID: 32317528 [TBL] [Abstract][Full Text] [Related]
9. A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo? Chan KM; Han J; Fang D; Gan H; Zhang Z Cell Cycle; 2013 Aug; 12(16):2546-52. PubMed ID: 23907119 [TBL] [Abstract][Full Text] [Related]
10. Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients. Neumann JE; Dorostkar MM; Korshunov A; Mawrin C; Koch A; Giese A; Schüller U J Neuropathol Exp Neurol; 2016 May; 75(5):408-14. PubMed ID: 26975364 [TBL] [Abstract][Full Text] [Related]
11. MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. Gallo M; Coutinho FJ; Vanner RJ; Gayden T; Mack SC; Murison A; Remke M; Li R; Takayama N; Desai K; Lee L; Lan X; Park NI; Barsyte-Lovejoy D; Smil D; Sturm D; Kushida MM; Head R; Cusimano MD; Bernstein M; Clarke ID; Dick JE; Pfister SM; Rich JN; Arrowsmith CH; Taylor MD; Jabado N; Bazett-Jones DP; Lupien M; Dirks PB Cancer Cell; 2015 Dec; 28(6):715-729. PubMed ID: 26626085 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Venneti S; Garimella MT; Sullivan LM; Martinez D; Huse JT; Heguy A; Santi M; Thompson CB; Judkins AR Brain Pathol; 2013 Sep; 23(5):558-64. PubMed ID: 23414300 [TBL] [Abstract][Full Text] [Related]
13. H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications? Gessi M; Gielen GH; Hammes J; Dörner E; Mühlen AZ; Waha A; Pietsch T J Neurooncol; 2013 Mar; 112(1):67-72. PubMed ID: 23354654 [TBL] [Abstract][Full Text] [Related]
14. H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas. Gielen GH; Gessi M; Hammes J; Kramm CM; Waha A; Pietsch T Am J Clin Pathol; 2013 Mar; 139(3):345-9. PubMed ID: 23429371 [TBL] [Abstract][Full Text] [Related]
15. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Karsy M; Guan J; Cohen AL; Jensen RL; Colman H Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343 [TBL] [Abstract][Full Text] [Related]
16. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Bender S; Tang Y; Lindroth AM; Hovestadt V; Jones DT; Kool M; Zapatka M; Northcott PA; Sturm D; Wang W; Radlwimmer B; Højfeldt JW; Truffaux N; Castel D; Schubert S; Ryzhova M; Seker-Cin H; Gronych J; Johann PD; Stark S; Meyer J; Milde T; Schuhmann M; Ebinger M; Monoranu CM; Ponnuswami A; Chen S; Jones C; Witt O; Collins VP; von Deimling A; Jabado N; Puget S; Grill J; Helin K; Korshunov A; Lichter P; Monje M; Plass C; Cho YJ; Pfister SM Cancer Cell; 2013 Nov; 24(5):660-72. PubMed ID: 24183680 [TBL] [Abstract][Full Text] [Related]
17. Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm. Gerges N; Fontebasso AM; Albrecht S; Faury D; Jabado N Genome Med; 2013; 5(7):66. PubMed ID: 23906214 [TBL] [Abstract][Full Text] [Related]
18. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations. Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431 [TBL] [Abstract][Full Text] [Related]
19. The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. Lee J; Solomon DA; Tihan T J Neurooncol; 2017 Mar; 132(1):1-11. PubMed ID: 28064387 [TBL] [Abstract][Full Text] [Related]
20. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Sturm D; Witt H; Hovestadt V; Khuong-Quang DA; Jones DT; Konermann C; Pfaff E; Tönjes M; Sill M; Bender S; Kool M; Zapatka M; Becker N; Zucknick M; Hielscher T; Liu XY; Fontebasso AM; Ryzhova M; Albrecht S; Jacob K; Wolter M; Ebinger M; Schuhmann MU; van Meter T; Frühwald MC; Hauch H; Pekrun A; Radlwimmer B; Niehues T; von Komorowski G; Dürken M; Kulozik AE; Madden J; Donson A; Foreman NK; Drissi R; Fouladi M; Scheurlen W; von Deimling A; Monoranu C; Roggendorf W; Herold-Mende C; Unterberg A; Kramm CM; Felsberg J; Hartmann C; Wiestler B; Wick W; Milde T; Witt O; Lindroth AM; Schwartzentruber J; Faury D; Fleming A; Zakrzewska M; Liberski PP; Zakrzewski K; Hauser P; Garami M; Klekner A; Bognar L; Morrissy S; Cavalli F; Taylor MD; van Sluis P; Koster J; Versteeg R; Volckmann R; Mikkelsen T; Aldape K; Reifenberger G; Collins VP; Majewski J; Korshunov A; Lichter P; Plass C; Jabado N; Pfister SM Cancer Cell; 2012 Oct; 22(4):425-37. PubMed ID: 23079654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]